RESUMEN
Extranodal natural killer (NK)/T-cell lymphoma is an aggressive malignant disease that is associated with Epstein-Barr viral (EBV) infection. To date, the mechanism of viral entry into NK cells remains uncertain. Here, we investigated this mechanism using human NK cells in vitro. CD21 mRNA expression, an EBV-entry receptor, was transiently detected in NK cells after exosome treatment, and levels decreased after further culture. CD21 protein expression was also transiently transferred to NK cells after co-culture with an EBV-positive Burkitt lymphoma cell line (Raji) via trogocytosis. However, EBV did not infect NK cells through CD21-mediated trogocytosis. Unexpectedly, when NK cell leukemia cells, as well as primary NK cells, were treated with viral supernatant, EBV genes, but not RNA, were detected in the NK cells, at latency stage 0. Therefore, these results suggest that EBV-NK cell infection results from the direct transfer of viral episomes, independent of EBV-positive B cells.
Asunto(s)
Infecciones por Virus de Epstein-Barr/metabolismo , Herpesvirus Humano 4/fisiología , Células Asesinas Naturales/fisiología , Adulto , Linfocitos B , Línea Celular Tumoral , Antígenos Nucleares del Virus de Epstein-Barr , Exosomas , Femenino , Voluntarios Sanos , Herpesvirus Humano 4/patogenicidad , Humanos , Células Asesinas Naturales/virología , Masculino , Cultivo Primario de Células , Receptores de Complemento 3d/metabolismo , Receptores de Complemento 3d/fisiologíaRESUMEN
Marginal zone macrophages (MZM) are strategically located in the spleen, lining the marginal sinus where they sense inflammation and capture Ag from the circulation. One of the receptors expressed by MZM is scavenger receptor macrophage receptor with collagenous structure (MARCO), which has affinity for modified self-antigens. In this article, we show that engagement of MARCO on murine macrophages induces extracellular ATP and loss of CD21 and CD62L on marginal zone B cells. Engagement of MARCO also leads to reduction of Ag transport by marginal zone B cells and affects the subsequent immune response. This study highlights a novel function for MZM in regulating Ag transport and activation, and we suggest that MARCO-dependent ATP release regulates this through shedding of CD21 and CD62L. Because systemic lupus erythematosus patients were shown to acquire autoantibodies against MARCO, this highlights a mechanism that could affect a patient's ability to combat infections.
Asunto(s)
Antígenos/metabolismo , Linfocitos B/inmunología , Macrófagos/fisiología , Receptores de Complemento 3d/fisiología , Bazo/inmunología , Inmunidad Adaptativa , Adenosina Trifosfato/metabolismo , Animales , Selectina L/fisiología , Ratones , Receptores Inmunológicos/fisiologíaRESUMEN
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis because of the lack from erythrocyte surface of the complement regulators CD55 and CD59, with subsequent uncontrolled continuous spontaneous activation of the complement alternative pathway (CAP), and at times of the complement classic pathway. Here we investigate in an in vitro model the effect on PNH erythrocytes of a novel therapeutic strategy for membrane-targeted delivery of a CAP inhibitor. TT30 is a 65 kDa recombinant human fusion protein consisting of the iC3b/C3d-binding region of complement receptor 2 (CR2) and the inhibitory domain of the CAP regulator factor H (fH). TT30 completely inhibits in a dose-dependent manner hemolysis of PNH erythrocytes in a modified extended acidified serum assay, and also prevents C3 fragment deposition on surviving PNH erythrocytes. The efficacy of TT30 derives from its direct binding to PNH erythrocytes; if binding to the erythrocytes is disrupted, only partial inhibition of hemolysis is mediated by TT30 in solution, which is similar to that produced by the fH moiety of TT30 alone, or by intact human fH. TT30 is a membrane-targeted selective CAP inhibitor that may prevent both intravascular and C3-mediated extravascular hemolysis of PNH erythrocytes and warrants consideration for the treatment of PNH patients.
Asunto(s)
Factor H de Complemento/química , Eritrocitos/efectos de los fármacos , Hemoglobinuria Paroxística/sangre , Hemólisis/efectos de los fármacos , Proteínas de Fusión Oncogénica/farmacología , Receptores de Complemento 3d/química , Proteínas Recombinantes de Fusión/farmacología , Estudios de Casos y Controles , Células Cultivadas , Complemento C3/efectos adversos , Complemento C3/antagonistas & inhibidores , Complemento C3/farmacología , Factor H de Complemento/metabolismo , Factor H de Complemento/farmacología , Proteínas del Sistema Complemento/efectos adversos , Proteínas del Sistema Complemento/fisiología , Citoprotección/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Eritrocitos/fisiología , Hemoglobinuria Paroxística/patología , Humanos , Proteínas de Fusión Oncogénica/metabolismo , Unión Proteica , Receptores de Complemento 3d/metabolismo , Receptores de Complemento 3d/fisiología , Proteínas Recombinantes de Fusión/metabolismoRESUMEN
Multiple Sclerosis (MS) is characterised by a chronic inflammation and demyelination of brain and spinal cord with a yet unknown aetiology. Based on multiple epidemiological and immunological studies, which suggest a role of Epstein-Barr virus (EBV) infection in the pathogenesis of MS, we investigated CD21 (CR2, complement receptor type 2), which serves as the EBV receptor. Serum concentrations of soluble CD21 receptor (sCD21) were determined in MS patients and controls. In accordance with findings in other autoimmune disorders decreased sCD21 levels were found in MS patients. On ß-IFN treatment serum sCD21 concentrations further decreased. To explore the role of the CD21 gene for MS susceptibility and the altered CD21 levels in MS patients we performed exon sequencing of the CD21 gene. While we identified new single nucleotide polymorphism (SNP) and confirmed previously reported SNPs, none of the SNPs was associated with MS. Our findings demonstrate that sCD21 expression is altered in MS patients similar to other autoimmune diseases although no evidence was found for a specific role of the CD21 gene in MS.
Asunto(s)
Esclerosis Múltiple Crónica Progresiva/inmunología , Esclerosis Múltiple Recurrente-Remitente/inmunología , Receptores de Complemento 3d/fisiología , Adulto , Estudios de Casos y Controles , Predisposición Genética a la Enfermedad , Humanos , Interferón beta/genética , Interferón beta/fisiología , Interferón beta/uso terapéutico , Persona de Mediana Edad , Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico , Esclerosis Múltiple Crónica Progresiva/genética , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/genética , Esclerosis Múltiple Recurrente-Remitente/metabolismo , Polimorfismo de Nucleótido Simple , Regiones Promotoras Genéticas/inmunología , Receptores de Complemento 3d/sangre , Receptores de Complemento 3d/genética , Análisis de Secuencia de ADN , Adulto JovenRESUMEN
Exosomes are nano-sized membrane vesicles released from a wide variety of cells, formed in endosomes by inward budding of the endosomal limiting membrane. They have immune stimulatory-, inhibitory-, or tolerance-inducing effects, depending on their cellular origin, which is why they are investigated for use in vaccine and immune therapeutic strategies. In this study, we explored whether exosomes of different origins and functions can selectively target different immune cells in human peripheral blood. Flow cytometry, confocal laser scanning microscopy, and multispectral imaging flow cytometry (ImageStream) revealed that exosomes derived from human monocyte-derived dendritic cells and breast milk preferably associated with monocytes. In contrast, exosomes from an EBV-transformed B cell line (LCL1) preferentially targeted B cells. This was not observed for an EBV(-) B cell line (BJAB). Electron microscopy, size-distribution analysis (NanoSight), and a cord blood transformation assay excluded the presence of virions in our LCL1 exosome preparations. The interaction between LCL1-derived exosomes and peripheral blood B cells could be blocked efficiently by anti-CD21 or anti-gp350, indicating an interaction between CD21 on B cells and the EBV glycoprotein gp350 on exosomes. The targeting of LCL1-derived exosomes through gp350-CD21 interaction strongly inhibited EBV infection in B cells isolated from umbilical cord blood, suggesting a protective role for exosomes in regulating EBV infection. Our finding also suggests that exosome-based vaccines can be engineered for specific B cell targeting by inducing gp350 expression.
Asunto(s)
Subgrupos de Linfocitos B/inmunología , Subgrupos de Linfocitos B/virología , Infecciones por Virus de Epstein-Barr/inmunología , Infecciones por Virus de Epstein-Barr/prevención & control , Exosomas/inmunología , Herpesvirus Humano 4/inmunología , Glicoproteínas de Membrana/metabolismo , Receptores de Complemento 3d/fisiología , Proteínas de la Matriz Viral/metabolismo , Subgrupos de Linfocitos B/metabolismo , Línea Celular Transformada , Membrana Celular/inmunología , Membrana Celular/metabolismo , Membrana Celular/virología , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Células Dendríticas/virología , Exosomas/metabolismo , Exosomas/virología , Humanos , Lactancia , Leche Humana/inmunología , Leche Humana/metabolismo , Leche Humana/virología , Monocitos/inmunología , Monocitos/metabolismo , Monocitos/virología , Unión Proteica/inmunología , Receptores de Complemento 3d/biosíntesis , Proteínas Estructurales Virales/metabolismoRESUMEN
Intestinal ischemia-reperfusion (IR)-induced damage requires complement receptor 2 (CR2) for generation of the appropriate natural Ab repertoire. Pathogenic Abs recognize neoantigens on the ischemic tissue, activate complement, and induce intestinal damage. Because C3 cleavage products act as ligands for CR2, we hypothesized that CR2(hi) marginal zone B cells (MZBs) require C3 for generation of the pathogenic Abs. To explore the ability of splenic CR2(+) B cells to generate the damaging Ab repertoire, we adoptively transferred either MZBs or follicular B cells (FOBs) from C57BL/6 or Cr2(-/-) mice into Rag-1(-/-) mice. Adoptive transfer of wild type CR2(hi) MZBs but not CR2(lo) FOBs induced significant damage, C3 deposition, and inflammation in response to IR. In contrast, similarly treated Rag-1(-/-) mice reconstituted with either Cr2(-/-) MZB/B1 B cells (B1Bs) or FOBs lacked significant intestinal damage and displayed limited complement activation. To determine whether C3 cleavage products are critical in CR2-dependent Ab production, we evaluated the ability of the natural Ab repertoire of C3(-/-) mice to induce damage in response to IR. Infusion of C3(-/-) serum into Cr2(-/-) mice restored IR-induced tissue damage. Furthermore, Rag-1(-/-) mice sustained significant damage after infusion of Abs from C3(-/-) but not Cr2(-/-) mice. Finally, adoptive transfer of MZBs from C3(-/-) mice into Rag-1(-/-) mice resulted in significant tissue damage and inflammation. These data indicate that CR2 expression on MZBs is sufficient to induce the appropriate Abs required for IR-induced tissue damage and that C3 is not critical for generation of the pathogenic Abs.
Asunto(s)
Autoanticuerpos/biosíntesis , Subgrupos de Linfocitos B/inmunología , Complemento C3/fisiología , Receptores de Complemento 3d/fisiología , Bazo/inmunología , Traslado Adoptivo , Animales , Autoanticuerpos/uso terapéutico , Subgrupos de Linfocitos B/patología , Subgrupos de Linfocitos B/trasplante , Células Cultivadas , Complemento C3/deficiencia , Proteínas de Homeodominio/genética , Inmunofenotipificación , Mucosa Intestinal/irrigación sanguínea , Mucosa Intestinal/inmunología , Mucosa Intestinal/patología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores de Complemento 3d/biosíntesis , Receptores de Complemento 3d/deficiencia , Daño por Reperfusión/inmunología , Daño por Reperfusión/patología , Daño por Reperfusión/terapia , Bazo/metabolismo , Bazo/patologíaRESUMEN
Ischemia reperfusion injury (IRI) is an unavoidable event during solid organ transplantation and is a major contributor to early graft dysfunction and subsequent graft immunogenicity. In a therapeutic paradigm using targeted complement inhibitors, we investigated the role of complement, and specifically the alternative pathway of complement, in IRI to heart isografts. Mouse heterotopic isograft heart transplants were performed in C57BL/6 mice treated with a single injection of either CR2-Crry (inhibits all complement pathways) or CR2-fH (inhibits alternative complement pathway) immediately posttransplantation. Transplanted hearts were harvested at 12 and 48 h for analysis. Both inhibitors resulted in a significant reduction in myocardial IRI, as measured by histology and serum cardiac troponin I levels. Furthermore, compared with untreated controls, both inhibitors reduced graft complement deposition, neutrophil and macrophage infiltration, adhesion molecule expression (P-selectin, E-selectin, and I-CAM-1), and proinflammatory cytokine expression (TNF-α, IL-1ß, KC, and MCP-1). The reduction in myocardial damage and cellular infiltration was not significantly different between CR2-Crry- and CR2-fH-treated mice, although adhesion molecule and cytokine levels were significantly lower in CR2-Crry-treated mice compared with CR2-fH-treated mice. In conclusion, the alternative complement pathway plays a major contributing role in myocardial IRI after heart transplantation, and local (targeted) complement inhibition has the potential to provide an effective and safe therapeutic strategy to reduce graft injury. Although total complement blockade may be somewhat more efficacious in terms of reducing inflammation, specific blockade of the alternative pathway is likely to be less immunosuppressive in an already immunocompromised recipient.
Asunto(s)
Factor H de Complemento/fisiología , Proteínas Inactivadoras de Complemento/fisiología , Vía Alternativa del Complemento/inmunología , Trasplante de Corazón/inmunología , Daño por Reperfusión Miocárdica/prevención & control , Proteínas Recombinantes de Fusión/fisiología , Animales , Factor H de Complemento/uso terapéutico , Proteínas Inactivadoras de Complemento/uso terapéutico , Citocinas/antagonistas & inhibidores , Citocinas/biosíntesis , Sistemas de Liberación de Medicamentos/métodos , Trasplante de Corazón/patología , Recuento de Leucocitos , Macrófagos/inmunología , Macrófagos/metabolismo , Macrófagos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Daño por Reperfusión Miocárdica/inmunología , Daño por Reperfusión Miocárdica/patología , Neutrófilos/inmunología , Neutrófilos/metabolismo , Neutrófilos/patología , Distribución Aleatoria , Receptores de Complemento 3d/fisiología , Receptores de Complemento 3d/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Trasplante HomólogoAsunto(s)
Integrina alfaXbeta2/sangre , Antígeno de Macrófago-1/sangre , Receptores de Complemento 3b/sangre , Receptores de Complemento 3d/sangre , Biomarcadores/sangre , Ensayo de Inmunoadsorción Enzimática/métodos , Citometría de Flujo/métodos , Humanos , Integrina alfaXbeta2/química , Integrina alfaXbeta2/fisiología , Síndrome de Deficiencia de Adhesión del Leucocito/diagnóstico , Lupus Eritematoso Sistémico/diagnóstico , Antígeno de Macrófago-1/química , Antígeno de Macrófago-1/fisiología , Fagocitosis , Receptores de Complemento 3b/química , Receptores de Complemento 3b/fisiología , Receptores de Complemento 3d/química , Receptores de Complemento 3d/fisiología , Valores de Referencia , Manejo de EspecímenesRESUMEN
The alternative pathway (AP) of complement is required for the induction of collagen Ab-induced arthritis (CAIA) in mice. The objective of this study was to examine the effect of a recombinant AP inhibitor containing complement receptor 2 and factor H (CR2-fH) on CAIA in mice. CR2 binds to tissue-fixed activation fragments of C3, and the linked fH is a potent local inhibitor of the AP. CAIA was induced in C57BL/6 mice by i.p. injections of 4 mAb to type II collagen (CII) on day 0 and LPS on day 3. PBS or CR2-fH (250 or 500 microg) were injected i.p. 15 min after the mAb to CII on day 0 and 15 min after LPS on day 3; the mice were sacrificed on day 10. The disease activity score (DAS) was decreased significantly (p < 0.001) in both groups receiving CR2-fH compared with the PBS. Histology scores for inflammation, pannus, bone damage, and cartilage damage decreased in parallel with the DAS. C3 deposition in the synovium and cartilage was significantly reduced (p < 0.0001) in the mice treated with CR2-fH. In vitro studies with immune complexes containing type II collagen and mAb to CII showed that CR2-fH specifically inhibited the AP with minimal effect on the classical pathway (CP) and no effect on the lectin pathway (LP). The relative potency of CR2-fH in vitro was superior to mAbs to factor B and C5. Thus, CR2-fH specifically targets and inhibits the AP of complement in vitro and is effective in CAIA in vivo.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Artritis Experimental/inmunología , Colágeno Tipo II/inmunología , Factor H de Complemento/fisiología , Proteínas Inactivadoras de Complemento/fisiología , Vía Alternativa del Complemento/inmunología , Receptores de Complemento 3d/fisiología , Proteínas Recombinantes de Fusión/fisiología , Animales , Artritis Experimental/patología , Artritis Experimental/terapia , Bovinos , Factor H de Complemento/administración & dosificación , Proteínas Inactivadoras de Complemento/administración & dosificación , Combinación de Medicamentos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores de Complemento 3d/administración & dosificación , Proteínas Recombinantes de Fusión/administración & dosificaciónRESUMEN
Complement receptor proteins CR2 (CD21) and CR1 (CD35) have been identified as components of the murine B cell co-receptor complex. Gene expression profiles between naïve WT, C3-/-, and CD21/35-/- B cells demonstrate enhanced expression of a Ca(2+)-modulating gene, Pcp4, in WT mice compared to the complement-deficient animals. Increased expression of Pcp4 is also coincident with B cell maturation into end stage phenotypes. Prolonged activation of B cells via cross-linking of the BCR (but not CR1/CR2 alone) leads to increased expression of Pcp4 and suppressed Ca(2+) release. In total these data demonstrate that the expression of Pcp4 in naïve resting mature B cells is dependent upon tonic stimulation from the CR1/CR2 proteins via a C3 ligand, and that antigen specific B cell activation can also elevate Pcp4 expression that is coincident with suppression of calcium-dependent responses.
Asunto(s)
Complemento C3/fisiología , Regulación de la Expresión Génica , Proteínas del Tejido Nervioso/genética , Receptores de Complemento 3d/fisiología , Animales , Linfocitos B/metabolismo , Linfocitos B/fisiología , Diferenciación Celular/genética , Células Cultivadas , Complemento C3/genética , Complemento C3/metabolismo , Reactivos de Enlaces Cruzados/farmacología , Femenino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas del Tejido Nervioso/metabolismo , Proteínas Proto-Oncogénicas c-bcr/metabolismo , Proteínas Proto-Oncogénicas c-bcr/fisiología , Receptores de Complemento 3b/genética , Receptores de Complemento 3b/metabolismo , Receptores de Complemento 3d/genética , Receptores de Complemento 3d/metabolismo , Transducción de Señal/genética , Transducción de Señal/fisiología , Bazo/metabolismoRESUMEN
EBV infection has been implicated in the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF). Viral infection may occur from the early or late stage in IPF development. Whether alveolar epithelial cells, AECs, normally express EBV main receptor, CD21, remains uncertain. Such situations prompted us to exploit an efficient direct infection system to investigate EBV receptor repertoire in primary human AECs. Using human primary type 2 AECs, which have been grown in basal medium supplemented with 10 ng/ml Keratinocyte Growth Factor, and type 1 AECs, supplemented with Epithelial Growth Factor, both AEC lines express CD21 mRNA and protein with a significant increase in type 2 cells. Type 2 AECs have been exposed to TGFbeta1 and IL-4, whose expression is associated with IPF development. CD21 is highly expressed in type 2 AECs following IL-4 exposure. EBV bound to type 2 AECs membrane increases significantly following pre-treatment with IL-4 (p<0.001) and decreasing antagonizing CD21 receptor (p<0.01). 200 microg/ml G418-mediated selection of EBV-Neomycin resistant infected cells selected IL-4 pre-exposed type 2 AECs. Our study of a viral cell line model provides evidence to suggest that CD21-dependent viral entry plays a crucial role in type 2 AECs, indicative of an IL-4 response EBV infection in IPF.
Asunto(s)
Células Epiteliales/efectos de los fármacos , Infecciones por Virus de Epstein-Barr/patología , Herpesvirus Humano 4/fisiología , Interleucina-4/farmacología , Alveolos Pulmonares/efectos de los fármacos , Receptores de Complemento 3d/fisiología , Células Cultivadas , Células Epiteliales/inmunología , Células Epiteliales/metabolismo , Células Epiteliales/virología , Infecciones por Virus de Epstein-Barr/genética , Infecciones por Virus de Epstein-Barr/inmunología , Infecciones por Virus de Epstein-Barr/metabolismo , Herpesvirus Humano 4/efectos de los fármacos , Humanos , Fibrosis Pulmonar Idiopática/etiología , Fibrosis Pulmonar Idiopática/inmunología , Fibrosis Pulmonar Idiopática/virología , Alveolos Pulmonares/inmunología , Alveolos Pulmonares/metabolismo , Alveolos Pulmonares/virología , Receptores de Complemento 3d/antagonistas & inhibidores , Receptores de Complemento 3d/genética , Receptores de Complemento 3d/metabolismo , Mucosa Respiratoria/efectos de los fármacos , Mucosa Respiratoria/inmunología , Mucosa Respiratoria/metabolismo , Mucosa Respiratoria/virología , Células Th2/metabolismo , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/inmunología , Acoplamiento Viral/efectos de los fármacosAsunto(s)
Evolución Molecular , Receptores de Complemento 3b/genética , Receptores de Complemento 3d/genética , Animales , Convertasas de Complemento C3-C5/metabolismo , Vía Clásica del Complemento , Humanos , Sistema Inmunológico/química , Sistema Inmunológico/citología , Sistema Inmunológico/metabolismo , Ratones , Receptores de Complemento 3b/química , Receptores de Complemento 3b/fisiología , Receptores de Complemento 3d/química , Receptores de Complemento 3d/fisiologíaRESUMEN
Here we describe the spatiotemporal architecture, at high molecular resolution, of receptors and signaling molecules during the early events of mouse B cell activation. In response to membrane-bound ligand stimulation, antigen aggregation occurs in B cell antigen receptor (BCR) microclusters containing immunoglobulin (Ig) M and IgD that recruit the kinase Syk and transiently associate with the coreceptor CD19. Unexpectedly, CD19-deficient B cells were significantly defective in initiation of BCR-dependent signaling, accumulation of downstream effectors and cell spreading, defects that culminated in reduced microcluster formation. Hence, we have defined the dynamics of assembly of the main constituents of the BCR 'signalosome' and revealed an essential role for CD19, independent of the costimulatory molecule CD21, in amplifying early B cell activation events in response to membrane-bound ligand stimulation.
Asunto(s)
Antígenos CD19/fisiología , Linfocitos B/inmunología , Membrana Celular/metabolismo , Receptores de Antígenos de Linfocitos B/metabolismo , Animales , Antígenos CD19/metabolismo , Linfocitos B/metabolismo , Técnicas In Vitro , Péptidos y Proteínas de Señalización Intracelular/fisiología , Membrana Dobles de Lípidos , Activación de Linfocitos , Ratones , Microscopía Fluorescente , Proteínas Tirosina Quinasas/fisiología , Receptores de Complemento 3d/fisiología , Transducción de Señal , Quinasa SykRESUMEN
The complement system was discovered almost a century ago as an important effector in antibody-dependent killing of microorganisms. Since this early period much was learned aboutthe biochemistry and structure of complement proteins and their function in mediating inflammation. More recently, a prominent role for complement was identified in linkage of innate and adaptive immunity. In this review, I will discuss our current understanding of the importance of complement in enhancing the humoral immune response to both model antigens and pathogens. As discussed below, it is evident that the complement system participates in marking of "foreign" pathogens and "presenting" them to B cells in a manner that enhances both antibody production and long-term memory. In this special issue of Vaccine, we see examples of how complement is critical in the immune response to bacterial and viral pathogens. Moreover, the finding that most organisms have co-evolved proteins to evade complement detection underscores its importance in host protection.
Asunto(s)
Formación de Anticuerpos , Proteínas del Sistema Complemento/fisiología , Animales , Linfocitos B/inmunología , Linfocitos B/fisiología , Diferenciación Celular , Complemento C3d/fisiología , Humanos , Receptores de Complemento 3b/fisiología , Receptores de Complemento 3d/fisiologíaRESUMEN
Complement, complement receptors and natural antibody (IgM) are important factors in the immune response against pathogens. Previous studies have indicated a role for C3, the complement receptors CD35/CD21 (CR1/CR2), and IgM in the immune response to influenza virus. Nevertheless, their contribution to the long-term memory response to this pathogen remains unknown. To elucidate this role, we characterized the secondary response on mice deficient of CR1/CR2 (Cr2-/-), C3 (C3-/-), secreted IgM (micros-/-) and the double knockout C3-/-micros-/-. Overall, our results suggest that C3, IgM and CR1/CR2 play crucial roles in the maintenance of long-term memory to influenza virus, possibly through the development of memory B cells and long-term antibody secretion.
Asunto(s)
Complemento C3/fisiología , Inmunoglobulina M/fisiología , Memoria Inmunológica , Orthomyxoviridae/inmunología , Receptores de Complemento 3b/fisiología , Receptores de Complemento 3d/fisiología , Animales , Anticuerpos Antivirales/sangre , Inmunoglobulina G/sangre , Ratones , Ratones Endogámicos C57BLRESUMEN
A complex network of interactions exist between the innate and adaptive immune pathways, which act together to elicit a broad and durable host response following pathogen infection. The importance of the complement system in the host's defense against viruses has become increasingly clear as a result of detailed studies using transgenic mouse models that disrupt specific components of this host immune mechanism. We have utilized herpes simplex virus and replication-defective mutant strains to examine the impact of the complement system on development and maintenance of humoral immune responses. Here we review work from our group and others that highlights the central role that complement proteins C3 and C4 and complement receptors Cr1/Cr2 play during viral infection. We discuss the implications of these results in the context of pathogen infection and current vaccine strategies.
Asunto(s)
Complemento C3/fisiología , Herpes Simple/inmunología , Anticuerpos Antivirales/sangre , Humanos , Inmunidad Innata , Células Mieloides/fisiología , Receptores de Complemento 3d/fisiología , Simplexvirus/patogenicidadRESUMEN
Follicular dendritic cells (FDC) represent a major extracellular reservoir for HIV. A better understanding of the mechanisms of virion attachment to FDC may offer new avenues for reducing viral burdens in infected individuals. We used a murine model to investigate the establishment of extracellular HIV reservoirs in lymph nodes (LN). Consistent with findings in human tissues, CD21 was required for trapping of HIV to LN cells, as evidenced by significantly reduced virion binding when mice were pretreated with a C3 ligand-blocking anti-CD21 mAb and absence of virion trapping in CD21 knockout mice. Also consistent with findings in human tissues, the majority of HIV virions were associated with the FDC-enriched fraction of LN cell preparations. Somewhat surprisingly, HIV-specific Abs were not essential for HIV binding to LN cells, indicating that seeding of the FDC reservoir may begin shortly after infection and before the development of HIV-specific Abs. Finally, the virion-displacing potential for anti-CD21 mAbs was investigated. Treatment of mice with anti-CD21 mAbs several days after injection of HIV significantly reduced HIV bound to LN cells. Our findings demonstrate a critical role for CD21 in HIV trapping by LN cells and suggest a new therapeutic avenue for reducing HIV reservoirs.
Asunto(s)
Espacio Extracelular/inmunología , Espacio Extracelular/virología , Tejido Linfoide/inmunología , Tejido Linfoide/virología , Receptores de Complemento 3d/fisiología , Animales , Anticuerpos Bloqueadores/metabolismo , Sitios de Unión de Anticuerpos , Células Dendríticas Foliculares/inmunología , Células Dendríticas Foliculares/metabolismo , Células Dendríticas Foliculares/virología , Espacio Extracelular/metabolismo , VIH/inmunología , VIH/metabolismo , Infecciones por VIH/inmunología , Infecciones por VIH/prevención & control , Infecciones por VIH/virología , Humanos , Células K562 , Tejido Linfoide/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores de Complemento 3d/inmunología , Receptores de Complemento 3d/metabolismo , Receptores del VIH/antagonistas & inhibidores , Receptores del VIH/metabolismo , Virión/inmunología , Virión/metabolismoRESUMEN
Complement receptor type 2 (CR2) is a receptor that serves as an important interface between the complement system and adaptive immunity. Recent studies have shown that CR2 is also centrally involved in innate immunity, and one key area is the development of potentially pathogenic natural antibodies that target neo-epitopes revealed in ischemic tissue undergoing reperfusion. Mice lacking either total immunoglobulins or CR2 alone are protected from the development of ischemia-reperfusion injury, and this effect can be reversed by introducing CR2-sufficient B-1 cells or by transferring polyclonal natural IgM antibody from wild type mice as well as monoclonal antibodies that recognize phospholipids, DNA or non-muscle myosin. We will report at the XXI ICW an additional membrane-associated protein to which pathogenic IgM antibodies are directed. Whether B cells producing these natural antibodies are differentially selected in CR2-deficient mice is as yet not well understood, and the complement-related mechanism(s) whereby this differential repertoire selection process could occur have yet to be explored in any detail. In addition to this important role in innate immunity, CR2 can also act as a receptor for other components or activators of innate immunity. One such component is interferon-alpha, an anti-viral cytokine that binds CR2 and induces a component of its mRNA signature in B cells through this receptor. Other potential CR2 ligands are DNA and DNA-containing complexes such as chromatin. The biologic role of these CR2 interactions with interferon-alpha and DNA-containing complexes is not well understood, but may be important in the development of the autoimmune disease systemic lupus erythematosus that is characterized by enhanced interferon-alpha levels and loss of self tolerance to DNA-containing self antigens.
Asunto(s)
Anticuerpos/inmunología , Linfocitos B/inmunología , Inmunidad Innata , Receptores de Complemento 3d/fisiología , Animales , Autoinmunidad , ADN/metabolismo , Epítopos , Humanos , Interferón-alfa/metabolismo , Activación de Linfocitos , Receptores de Antígenos de Linfocitos B/fisiologíaRESUMEN
B-1b cells produce IgM natural antibodies against alpha1-3Galbeta1-4GlcNAc (alphaGal). These can be tolerized by nonmyeloablative induction of mixed chimerism using alphaGal-positive (alphaGal+) donor marrow. We assessed the role of CR1/2 in this model for induction of tolerance of B-1b cells. Mixed hematopoietic chimerism was induced in alpha1-3galactosyltransferase (GalT-/-) and GalT-/-Cr2-/- mice with alphaGal+ BALB/c marrow donors. Anti-alphaGal Ab and anti-alphaGal Ab-producing B cells became undetectable in GalT-/- chimeras, whereas they persisted in chimeric GalT-/-Cr2-/- mice. To determine whether CR1/2 expression on stromal cells and/or hematopoietic cells was critical for B-1-cell tolerance, we generated GalT-/- radiation chimeras in which CR1/CR2 was expressed on either stromal cells, hematopoietic cells, neither, or both. After induction of mixed chimerism from alphaGal+ allogeneic bone marrow (BM) donors, anti-alphaGal-producing B cells were rendered tolerant in reconstituted recipients expressing only stromal CR1/CR2. Our results suggest a possible role for follicular dendritic cells that pick up immune complexes via CR1/CR2 receptors in the tolerization of B-1b cells.
Asunto(s)
Anticuerpos , Formación de Anticuerpos , Linfocitos B/inmunología , Tolerancia Inmunológica/inmunología , Receptores de Complemento 3b/inmunología , Receptores de Complemento 3d/inmunología , Trisacáridos/inmunología , Animales , Trasplante de Médula Ósea , Células Madre Hematopoyéticas , Inmunoglobulina M , Ratones , Ratones Noqueados , Receptores de Complemento 3b/fisiología , Receptores de Complemento 3d/fisiología , Células del Estroma , Quimera por TrasplanteRESUMEN
The mechanisms that contribute to inflammatory damage following ischemic stroke are poorly characterized, but studies indicate a role for both complement and P-selectin. In this study, we show that compared with wild-type mice, C3-deficient mice showed significant improvement in survival, neurological deficit, and infarct size at 24 h after middle cerebral artery occlusion and reperfusion. Furthermore, P-selectin protein expression was undetectable in the cerebral microvasculature of C3-deficient mice following reperfusion, and there was reduced neutrophil influx, reduced microthrombus formation, and increased blood flow postreperfusion in C3-deficient mice. We further investigated the use of a novel complement inhibitory protein in a therapeutic paradigm. Complement receptor 2 (CR2)-Crry inhibits complement activation at the C3 stage and targets to sites of complement activation. Treatment of normal mice with CR2-Crry at 30 min postreperfusion resulted in a similar level of protection to that seen in C3-deficient mice in all of the above-measured parameters. The data demonstrate an important role for complement in cerebrovascular thrombosis, inflammation, and injury following ischemic stroke. P-selectin expression in the cerebrovasculature, which is also implicated in cerebral ischemia and reperfusion injury, was shown to be distal to and dependent on complement activation. Data also show that a CR2-targeted approach of complement inhibition provides appropriate bioavailability in cerebral injury to enable complement inhibition at a dose that does not significantly affect systemic levels of serum complement activity, a potential benefit for stroke patients where immunosuppression would be undesirable due to significantly increased susceptibility to lung infection.